Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2015

View Archived Issues

ADA highlights: ultra-long acting GLP-1/glucagon agonists for type 2 diabetes and obesity

Novel inhibitor of Plasmodium protein synthesis shows promise for malaria

Prism Pharma begins phase I/II study of C-82 topical gel

Five Prime Therapeutics begins phase I/II trial of FPA-008

Japanese team discloses Wnt signaling pathway inhibitors

Baxter spin-off Baxalta now in business

Versartis confirms removal of FDA partial hold on VRS-317 trial

Bristol-Myers Squibb patents TYK2 inhibitors

Lycera describes F1F0-ATPase inhibitors

Almirall reports JAK inhibitors

Quanticel Pharmaceuticals reports development of KDM1A inhibitors

Chong Kun Dang Holdings divulges HDAC6 inhibitors

[18F]AZC2, a novel PET probe for c-MET imaging

Scaffolds based on synthetic TCP and autologous cells for maxillofacial surgery

Strensiq receives first approval in Japan for hypophosphatasia

CAT-1004 receives FDA fast track designation for Duchenne muscular dystrophy

Novel PI3Kdelta inhibitor shows promise for the treatment of EBA

MD Anderson Cancer Center starts phase I trial of siRNA targeting EphA2

NIDA tests AZD-8529 for smoking cessation

Janssen opens daratumumab expanded access program in U.S.

FDA clears Celtaxsys to begin phase II trial of acebilustat for cystic fibrosis

Olanedine antiseptic approved in Japan

JNJ-42165279 enters phase II trial in social anxiety disorder

Ignyta collaborates with UCSF on proof-of-concept trial of entrectinib in metastatic melanoma

Celtic Biotech and Emory University agree to develop crotamine-based imaging agent

Celsion releases new interim data from DIGNITY breast cancer study of ThermoDox

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...